Patients with HER2- Breast Cancer are being recruited for participation in a research study involving immunotherapy and chemotherapy

IRB/UVA Tracking #
21855
Principal Investigator
Patrick M Dillon
Contact
Olena Glushakova
Contact Email
Contact Phone
434.409.6206
Official Trial Title
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer – A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have human epidermal growth factor 2 negative (HER2-) advanced breast cancer. The purpose of this study is to see whether taking decitabine and pembrolizumab (drugs that help the immune system fight cancer) before standard chemotherapy will improve the immune systems response to the cancer and to see how effective chemotherapy is in fighting cancer. This study will also look at side effects caused by using immunotherapy.

Participation may last 18 months. This includes screening, treatment, and follow-up periods. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02957968

Compensation

No Compensation